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Abstract
Background: Antimicrobial decision making in intensive care units (ICUs) is challenging. Unnecessary antimicrobials
contribute to the development of resistant pathogens, Clostridium difficile infection and drug related adverse events.
However, inadequate antimicrobial therapy is associated with mortality in critically ill patients. Antimicrobial stewardship
programs are increasingly being implemented to improve antimicrobial prescribing, but the optimal approach in the ICU
setting is unknown. We assessed the impact of an audit and feedback antimicrobial stewardship intervention on
antimicrobial use, antimicrobial costs, clinical outcomes and microbiologic outcomes in two ICUs with different patient
populations.
Methods: The audit and feedback intervention was implemented in a trauma and neurosurgery ICU (TNICU) and a
medical surgical ICU (MSICU) at a 465-bed teaching hospital in Toronto, Canada. ICU patients were reviewed Monday to
Friday by a physician and pharmacist with infectious diseases training. Recommendations related to appropriate
antimicrobial use were presented to ICU teams during a dedicated daily meeting. A controlled interrupted time series
analysis was used to compare outcomes in the 12 months before and after the intervention. Cardiovascular and coronary
care ICUs served as control units.
Results: Mean total monthly antimicrobial use in defined daily doses (DDD) per 1000 patient days was reduced 28 % in
the TNICU (1433 vs. 1037) but increased 14 % in the MSICU (1705 vs. 1936). In the time series analysis, total monthly
antimicrobial use in the TNICU decreased by 375 DDD per 1000 patient days (p < 0.0009) immediately following the
intervention, followed by a non-significant downward trend in use of −9 DDD per 1000 patient days (p = 0.56). No
significant changes in antimicrobial use were identified in the MSICU. Antimicrobial use temporarily increased in one
control unit and remained unchanged in the other. There were no changes in mortality, length of stay, readmission rate,
incidence of C. difficile infection or resistance patterns of E. coli and P. aeruginosa in either intervention unit.
Conclusions: Audit and feedback antimicrobial stewardship programs can lead to significant reductions in total
antimicrobial use in the ICU setting. However, this effect may be context-dependent and further work is needed to
determine the ingredients necessary for success.
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Background
Antimicrobial resistance is one of the most serious
threats to public health today [1]. It is well accepted that
antimicrobial use contributes to the development of
antimicrobial resistance, and studies have shown that up
to 50 % of antimicrobial use in clinical practice is in-
appropriate [2, 3]. Antimicrobial stewardship interven-
tions are increasingly being advocated as an important
strategy to increase the appropriateness of antimicrobial
prescribing, with the aim of preventing or delaying the
emergence of resistance [1, 3]. Potential additional bene-
fits of more appropriate antimicrobial use include a re-
duction in adverse outcomes, including Clostridium
difficile infection and drug reactions, as well as a reduc-
tion in healthcare costs [3–5]. The Centers for Disease
Control and Prevention, the World Health Organization
and the Infectious Diseases Society of America all en-
dorse antimicrobial stewardship programs as an effective
means to prevent the development and spread of anti-
microbial resistance [1, 6, 7].
One of the most promising antimicrobial stewardship
intervention strategies is prospective audit and feedback,
a technique shown to reduce antimicrobial use in
randomized-controlled trials [8, 9]. While most studies
evaluating prospective audit and feedback programs have
been conducted on medical and surgical wards, intensive
care units (ICUs) may be the setting with the greatest
potential impact [8–10]. The majority of critically ill
patients receive antimicrobials and as a result, these
units often have high levels of antimicrobial resistance
[10, 11]. On the other hand, inadequate initial therapy
has been associated with mortality in critically ill patients
[12]. To date, there have been few well-conducted studies
evaluating the impact of audit and feedback in ICUs
[11, 13–16]. We recently introduced an audit and
feedback program into two ICUs at St. Michael’s Hos-
pital. We used interrupted time series analysis to
evaluate the impact of our audit and feedback pro-




This study evaluated changes in antimicrobial use asso-
ciated with implementation of an antimicrobial steward-
ship audit and feedback program using a controlled
interrupted time series design [17]. We hypothesized
that implementation of audit and feedback would lead to
reduced antimicrobial use in both units.
Study Setting and Population
This study was performed in four adult ICUs at St. Mi-
chael’s Hospital, a 465-bed academic teaching hospital
in Toronto, Ontario, Canada. The intervention ICUs
included a 19-bed trauma and neurosurgery ICU
(TNICU) and a 24-bed medical and surgical ICU
(MSICU). The control ICUs included a 15-bed cardiovas-
cular surgery ICU (CVICU) and a 10-bed cardiac ICU
(CICU).
Antimicrobial use and other outcomes (see below) were
collected for all patients admitted to the ICUs during the
study period. Approval was obtained from the Research
Ethics Board at St. Michael’s Hospital. The Research Eth-
ics Board waived the need for informed consent since the
study used anonymous, aggregate, retrospective data.
Intervention
The audit and feedback intervention was introduced in
the TNICU on April 1, 2013 and in the MSICU on April
15, 2013. The pre-intervention and post-intervention pe-
riods were defined as April 1, 2012 to March 31, 2013
(pre-intervention) and May 1, 2013 to April 30, 2014
(post-intervention).
During the pre-intervention period, antibiotic selection
was performed at the discretion of the respective ICU
teams. During the post-intervention period, an infectious
diseases trained pharmacist and physician reviewed all
patients admitted to the intervention ICUs daily (week-
days only). Patients who remained in the ICU were reas-
sessed every weekday until ICU discharge. Prescribed
antimicrobials, as well as microbiology, laboratory and
diagnostic imaging results were reviewed. During a daily,
dedicated 30 minute meeting, the ICU team presented
additional clinical details for each patient and the stew-
ardship team provided recommendations on antimicro-
bial use to the team. Recommendations were made
verbally and documented in the chart only if requested
by the ICU team. The ICU team maintained prescribing
autonomy. For patients followed by the infectious dis-
eases service, recommendations were provided to the in-
fectious diseases team, rather than the ICU team, to
avoid conflicting advice. Advice was not provided on pa-
tients with cystic fibrosis (CF) as their antibiotic man-
agement was determined by a separate CF service,
whose physicians have greater expertise in the manage-
ment of this patient population.
This initiative was part of an Ontario-wide quality im-
provement project (Council of Academic Hospitals of
Ontario Antimicrobial Stewardship Program in Intensive
Care Units Project) to introduce audit and feedback pro-
grams into ICUs.
Outcomes
The primary outcome was total systemic (oral or paren-
teral) antimicrobial use in each ICU, measured in
defined daily doses (DDD) per 1000 patient days
per month [http://www.whocc.no/atc_ddd_index/]. Anti-
microbial data was acquired from the pharmacy
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department as total grams dispensed to the unit per
month (see Additional file 1). Patient days were obtained
from the hospital’s administrative database.
Secondary outcome measures included the use of pre-
specified antibiotic agents or classes, antimicrobial costs,
antimicrobial susceptibility for Escherichia coli and
Pseudomonas aeruginosa, Clostridium difficile infection
incidence, and clinical outcomes, including monthly ICU
mortality rates, ICU length of stay and 48 hour ICU re-
admission rates.
Antimicrobial costs were calculated as Canadian dol-
lars per patient day per month and were obtained from
the pharmacy database. The number and antimicrobial
susceptibility of P. aeruginosa and E. coli isolates from
clinical samples were assessed. These organisms were se-
lected a priori since they were the two most commonly
isolated Gram negative organisms in our intervention
ICUs. Only the first isolate per patient per hospital stay
was included, unless there was a change in antimicrobial
susceptibility. In this case, subsequent isolates with add-
itional antimicrobial resistance were also included. Spec-
imens were accepted from all clinical sites cultured with
two exceptions. Respiratory specimens from patients
with cystic fibrosis were excluded since these patients
are often chronically colonized with multi-drug resistant
organisms that, in most instances, reflect antimicrobial
use prior to arrival in the ICU. Additionally, screening
swabs collected for infection control purposes were not
included. Susceptibility data was obtained from the clin-
ical microbiology laboratory information system.
Incidence rates of nosocomial C. difficile infection
were calculated based on prospective surveillance con-
ducted by Infection Prevention and Control. Clinical
outcomes, including ICU mortality rates, ICU length of
stay and 48 hour ICU readmission rates, were available
via the Critical Care Information System (CCIS) [http://
www.health.gov.on.ca/en/pro/programs/criticalcare/
ccis.aspx].
In addition to the above outcomes, age, sex, admit-
ting diagnosis, ventilator utilization ratio (calculated
as ventilator days divided by patient days) and mean
multiple organ dysfunction score were obtained using
data from the CCIS. Other factors likely to influence
antimicrobial use, including monthly rates of febrile
respiratory illness and influenza, were also collected.
Finally, data related to cystic fibrosis was documented.
St. Michael’s Hospital has the largest adult CF
program in North America [http://www.stmichaels
hospital.com/programs/cysticfibrosis/index.php]. Pa-
tients with CF frequently receive prolonged durations
of multiple, broad spectrum antimicrobials at high
doses. Therefore, data collection included the number
of patient days per month in each unit attributable to
patients with cystic fibrosis (through International
Classification of Diseases 10th version - ICD-10 codes)
as this was a potential confounder with respect to
overall antimicrobial use.
Controls
The CVICU and CICU served as control ICUs because
these units did not receive the intervention. There was
minimal overlap between attending physicians in control
and intervention units. H2 blocker and proton pump in-
hibitors, measured in DDD per 1000 patient days, were
used as negative tracer medications, since prescription
of these agents should not have been affected by the
intervention.
Statistical Analysis
The primary outcome was assessed by segmented re-
gression analysis of interrupted time series data [17]. This
method estimates changes in the level and trend for the
outcome (i.e. antimicrobial use) after the intervention
while controlling for pre-existing trends and temporal
confounders. The analysis was performed separately for
each of the intervention and control ICUs as well as for
each of the tracer medications.
Traditional sample size calculations are not appropri-
ate for time series analysis. Instead, it is recommended
that there are a minimum of 12 data points before the
intervention and 12 data points afterwards as in our
study [17]. Autocorrelation was assessed by computing
the Durbin-Watson statistic. Since evidence of autocor-
relation was detected, all analyses were performed using
autoregression in SAS (Version 9.4, Cary, North Caro-
lina) with correction for first and second order autocor-
relation using the maximum likelihood method. The
assumptions of normality, homoscedasticity, and linear-
ity were assessed using the Q-Q plot of residuals, plot of
residuals against predicted values and plots of residuals
against each variable in the regression model respect-
ively. This same method was used to assess changes in
tracer medications.
Categorical variables were assessed using the Chi-
square test or Fisher’s exact test, continuous variables
were assessed using the t-test or Wilcoxon rank sum
test, and rates were assessed using incidence rate ratios.
All tests of significance were two-tailed and a p-value
less than 0.05 was considered statistically significant. For
the analyses of specific antibiotic agents and classes and
for the analyses of resistance of organisms, Bonferroni
corrections were used to correct for multiple hypothesis
testing; for the classes of antimicrobials and individual
antibiotics, a p-value of < 0.0028 was considered sta-
tistically significant, and for resistance tests, a p-value
of < 0.0033 was considered significant. Statistical ana-
lysis was performed using SAS (Version 9.4, Cary,
North Carolina) with the exception of incidence rate
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During the pre-intervention period, 1330 patients
were admitted to the TNICU, corresponding to 6049
patient days, and 1305 patients were admitted to the
MSICU, corresponding to 7230 patient days. In the
post-intervention period, there were 1387 patients ad-
mitted to the TNICU, making up 6254 patient days,
and 1369 patients admitted to the MSICU, for a total
of 7488 patient days. There were no significant differ-
ences in sex, rates of febrile respiratory illness or
influenza between the two intervention periods
(Table 1). In the TNICU, there were minor differences
in admitting diagnosis between the two periods. In
the MSICU, there were differences in age and admit-
ting diagnosis between the two periods. The mean
multiple organ dysfunction score in the MSICU was
lower in the post-intervention period. The most sig-
nificant difference was a four-fold increase in patient
days attributable to patients with cystic fibrosis in the
post-intervention period in the MSICU (p < 0.0001).
Antimicrobial Use
TNICU
The mean total monthly antimicrobial use in the TNICU
decreased by 28 % from 1433 DDD per 1000 patient
days to 1037 DDD per 1000 patient days after the inter-
vention. Time series analysis demonstrated a significant
decrease in the level of antimicrobial use by 375 DDD
per 1000 patient days immediately after the intervention
(standard error, 94; p = 0.0009) (Table 2, Fig. 1). There
was no significant change in the trend of antimicrobial
use. With respect to specific agents and classes of anti-
microbials, there was a significant reduction in antibac-
terials by 29 % (p = 0.0001), antibiotics with activity
Table 1 Patient characteristics for those in the trauma and neurosurgery intensive care unit and medical surgical intensive care unit
during the pre- and post-intervention periods.
Unit Characteristic Pre-intervention period Post-intervention period p-value
TNICU
Admissions n = 1330 n = 1387
Age, mean (SD) 55 (18) b 56 (18) 0.12
Male 757 (57) 801 (58) 0.66
Admitting diagnosis 0.0086
Neurological 879 (66) 937 (68)
Trauma 327 (25) 364 (26)
Other 124 (9) 86 (6)
Ventilator utilization ratio 0.59 0.60 0.80
Multiple organ dysfunction score, mean (SD) 2.39 (0.34) 2.32 (0.24) 0.56a
Febrile respiratory illness rate, cases per 1000 patient days 0.5 0.3 0.66
Influenza rate, cases per 1000 patient days 0 0 1.00
Patient days attributable to cystic fibrosis 0 (0) 0 (0) –
MSICU
Admissions n = 1305 n = 1369
Age, mean (SD) 61 (17) 59 (18) 0.016
Male 784 (60) 833 (61) 0.68
Admitting diagnosis 0.0082
Respiratory 192 (15) 265 (19)
Gastrointestinal 142 (11) 123 (9)
Neurological 88 (7) 95 (7)
Other 883 (68) 886 (65)
Ventilator utilization ratio 0.69 0.69 0.77
Multiple organ dysfunction score, mean (SD) 4.26 (0.38) 3.83 (0.33) 0.0061a
Febrile respiratory illness rate, cases per 1000 patient days 21.4 17.6 0.099
Influenza rate, cases per 1000 patient days 1.7 2.1 0.52
Patient days attributable to cystic fibrosis 68 (1) 277 (4) <0.0001
Data are number (%) unless otherwise indicated. All p-values calculated using Chi-square unless otherwise noted. SD, standard deviation; TNICU, trauma and
neurosurgery intensive care unit; MSICU, medical surgical intensive care unit. at-test; b2 data points missing
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against Pseudomonas species by 44 % (p < 0.0001) and
fluoroquinolones by 80 % (p < 0.0001) (Table 3) .
MSICU
The mean total monthly antimicrobial use in the MSICU
was 1705 DDD per 1000 patient days before the inter-
vention and 1936 DDD per 1000 patient days after the
intervention. The time series analysis showed a non-sig-
nificant increase in level of antimicrobial use of 297 DDD
per 1000 patient days (standard error, 249; p = 0.25) and a
non-significant decreasing trend in antimicrobial use of
−30 DDD per 1000 patient days per month (standard
error, 35; p = 0.40) after the intervention (Table 2, Fig. 1).
There were no significant changes in the use of the spe-
cific agents or classes of antimicrobials (Table 3).
Control ICUs
The mean total monthly antimicrobial use in the CVICU
was 969 DDD per 1000 patient days before the interven-
tion and 1071 DDD per 1000 patient days after the
intervention. The time series analysis did not show any
significant change in level or trend of antimicrobial use
after the intervention. The mean total monthly anti-
microbial use in the CICU was 545 DDD per 1000 pa-
tient days before the intervention and 599 DDD per
1000 patient days after the intervention. Time series
analysis demonstrated a significant increase in the level
of antimicrobial use by 454 DDD per 1000 patient days
(standard error, 128; p = 0.0023) immediately coinciding
with the onset of the intervention period, but a significant
decrease in the trend of antimicrobial use of −50 DDD per
1000 patient days per month thereafter (standard error, 19;
p = 0.017) (Table 2).
Tracer Medications
There were no significant changes in the level or trend
of H2 blocker or proton pump inhibitor use in the TNICU
or MSICU post-intervention (Table 4).
Antimicrobial Costs
The mean total cost of antimicrobials in the TNICU de-
creased from $18.40 per patient day (standard deviation
$4.03 per patient day) before the intervention to $14.53
per patient day (standard deviation $4.48 per patient
day) after the intervention (p = 0.017). There was no sig-
nificant change in the mean cost of antimicrobials in the
MSICU with a mean total cost of antimicrobials of
$33.87 per patient day (standard deviation $19.42 per
patient day) before the intervention and $40.29 (stand-
ard deviation $15.88 per patient day) after the interven-
tion (p = 0.14).
Clinical Outcomes
There were no significant changes in the TNICU or
MSICU mortality, length of stay in the ICU or propor-
tion of patients readmitted to the ICU between the pre-
and post- intervention periods (Table 5).
Microbiologic Outcomes
There were no statistically significant differences in the
antimicrobial susceptibility of E. coli or P. aeruginosa
isolates in the TNICU or the MSICU between the pre-
and post-intervention periods at the pre-specified Bon-
ferroni corrected significance threshold of 0.0033
(Table 6). The rate of C. difficile infection in the TNICU
decreased from 0.66 cases per 1000 patient days pre-
intervention to 0.48 cases per 1000 patient days post-
intervention, however, the result was not statistically sig-
nificant (p = 0.69). There was a non-significant decrease
in the rate of C. difficile infection in the MSICU from
1.5 cases per 1000 patient days pre-intervention to 0.80
cases per 1000 patient days post-intervention (p = 0.21).
A post-hoc analysis revealed there was also a non-
significant decrease in the incidence of C. difficile infec-
tion in both control ICUs.
Discussion
In this study, we demonstrated that an audit and
feedback antimicrobial stewardship intervention, when
introduced simultaneously into two distinct ICUs,
yielded different results. In the TNICU, an immediate
and clinically significant drop in antimicrobial use
was observed with an overall reduction of 28 %. In
the MSICU, there was no appreciable change in anti-
microbial use attributable to the intervention. No sig-
nificant immediate reductions were noted in the
control ICUs or with the tracer medications, suggest-
ing that the intervention was responsible for the
Table 2 Autoregressive model for total antimicrobial use per month measured in defined daily doses per 1000 patient days for
intervention and control intensive care units.
Unit Baseline level Baseline trend Change in level (standard error) p-value Change in trend (standard error) p-value
TNICU 1427 1 −375 (94) 0.0009 −9 (15) 0.56
MSICU 1626 10 297(249) 0.25 −30 (35) 0.40
CVICU 1009 −3 169(177) 0.35 −12 (25) 0.63
CICU 591 −7 454 (128) 0.0023 −50 (19) 0.017
TNICU, trauma and neurosurgery intensive care unit; MSICU, medical surgical intensive care unit; CVICU, cardiovascular intensive care unit; CICU, cardiac intensive
care unit.
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change in the TNICU. However, this does not explain
why the intervention was successful in only one of
two intervention ICUs, an unexpected finding given
that the stewardship team and the format of the
intervention were identical in both units.
The magnitude of the result in the TNICU is similar
to results reported in a systematic review of stewardship
interventions in critical care units, where reductions in
antimicrobial use of 11–38 % were observed [13]. Stud-
ies using audit and feedback strategies in critical care
Fig. 1 Total antimicrobial use per month pre- and post-intervention for the trauma and neurosurgery intensive care unit (a) and the medical
surgical intensive care unit (b). The time series analysis demonstrated a significant decrease in the level of antimicrobial use in the trauma and
neurosurgery intensive care unit by 375 defined daily doses per 1000 patient days immediately after the intervention (p = 0.0009) but no significant
change in antimicrobial use in the medical surgical intensive care unit.
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units showed reductions in antimicrobial use ranging
from 8 %–22 % [11, 15, 16, 18, 19]. However, some stew-
ardship studies have focused their intervention and out-
come on ‘targeted antimicrobials’ [20]. As a result, these
studies have shown significant reductions in targeted an-
timicrobials, without measuring compensatory increases
that can occur in other antimicrobials, a phenomenon
known as “squeezing of the balloon” [21]. Therefore, a
Table 3 Comparison of the use of specific antimicrobial classes and agents measured in defined daily doses per 1000 patient days
in the pre- and post-intervention periods. P-values meeting the pre-specified Bonferroni corrected significance threshold are bolded.
Unit Class or Agent Pre-intervention mean (SD) Post-intervention mean (SD) p-value
TNICU
antibacterials 1409 (203) 1001 (232) 0.0001
antibacterials with antipseudomonal activity 349 (89) 195 (62) <0.0001
antifungals 24(24) 36 (25) 0.33
penicillin 15 (21) 19 (24) 0.63
ampicillin 86 (67) 52 (39) 0.24
cloxacillin 337(127) 235(128) 0.068
piperacillin-tazobactam 72 (15) 71 (30) 0.71
cefazolin 189 (55) 138 (43) 0.028
ceftriaxone 78 (35) 67 (41) 0.29
ceftazidime 52 (40) 34 (21) 0.41
ertapenem 4 (7) 3 (7) 0.47
meropenem 11 (18) 22 (32) 0.23
imipenem 9 (10) 16 (14) 0.20
fluoroquinolones 210 (81) 43 (32) <0.0001
TMP-SMX 76 (73) 83 (57) 0.67
azithromycin 12 (13) 21 (16) 0.20
vancomycin 203 (110) 134 (52) 0.068
aminoglycosides 4 (8) 8 (10) 0.18
MSICU
antibacterials 1547 (274) 1715 (263) 0.16
antibacterials with antipseudomonal activity 445 (136) 588 (196) 0.028
antifungals 177 (195) 202 (124) 0.14
penicillin 55 (48) 44 (68) 0.29
ampicillin 81 (58) 94 (89) 0.98
cloxacillin 166 (119) 136(66) 0.93
piperacillin-tazobactam 197 (53) 200 (34) 0.98
cefazolin 68 (29) 83 (30) 0.35
ceftriaxone 97 (27) 113 (40) 0.48
ceftazidime 28 (21) 32 (29) 0.98
ertapenem 19 (24) 15 (15) 0.77
meropenem 28 (48) 55 (51) 0.033
imipenem 49 (35) 47 (28) 0.84
fluoroquinolones 138 (49) 180 (60) 0.078
TMP-SMX 118 (93) 85 (41) 0.63
azithromycin 101 (42) 132 (53) 0.11
vancomycin 153 (38) 175 (43) 0.18
aminoglycosides 29 (34) 55 (43) 0.088
All p-values calculated using Wilcoxon rank sum test. SD, standard deviation; TNICU, trauma and neurosurgery intensive care unit; MSICU, medical surgical
intensive care unit; TMP-SMX, trimethoprim-sulfamethoxazole.
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strength of our study, is that it demonstrated a reduction
in overall antimicrobial use, rather than simply the use
of specific agents.
Another important finding in the TNICU was a 44 %
reduction in the use of antimicrobials effective against
Pseudomonas species. This is important, since Pseudo-
monas species are intrinsically drug resistant organisms
and thus it is likely beneficial to conserve antibiotics
used to treat these organisms. Furthermore, the reduc-
tion in fluoroquinolone use was important since these
antibiotics have been associated with a low threshold for
emergence of resistance as well as an increased risk of
development of Clostridium difficile infection [22, 23].
Furthermore, substantial overall cost savings of 21 %
were seen in the post-intervention period.
In the MSICU, antimicrobial use was unchanged.
There are several potential factors that may have con-
tributed to the absence of a measurable effect of the
stewardship intervention. First, because appropriateness
of therapy was not measured as one of our study out-
comes, it is possible that antimicrobial prescribing was
already ‘more appropriate’ in the MSICU. Alternatively,
because the MSICU patient population is older, more
critically ill and more likely to have an infection present
at the time of admission, differences in patient popu-
lation may have contributed to these findings. Overall
antibiotic use may have been more driven by initial
empiric therapy, potentially resulting in the ICU team
being less likely to follow stewardship recommenda-
tions. Finally, the two units have different leadership,
cultures, educational structures and decision-making
processes.
One additional consideration is that in the post-
intervention period there was a 4-fold increase in the
number of patient days associated with patients with
cystic fibrosis in the MSICU. CF patients often harbor
multi-drug resistant bacteria [24]. They are also often
treated with multiple antimicrobials and higher doses of
antimicrobials than other adults, thus their admission to
the MSICU could significantly increase monthly anti-
microbial use [25, 26]. It would have been desirable to
exclude these patients from the analysis since they were
not included in the intervention; however, this was not
possible due to limitations related to the hospital infor-
mation system used to quantify antimicrobial use, which
was not able to link usage data to individual patients. In-
stead, the primary analysis was repeated with adjustment
for the number of CF patient days per month, and the
overall results did not change. There were other statisti-
cally significant differences in patient characteristics in
the MSICU in the post intervention period in compari-
son to the pre-intervention period including a different
distribution of admitting diagnoses and a lower multiple
organ dysfunction score; however, these differences do
Table 4 Autoregressive model for use of tracer medications per month in each intervention intensive care unit measured in defined
daily doses per 1000 patient days.
Unit Variable Baseline level Baseline trend Change in level (standard error) p-value Change in trend (standard error) p-value
TNICU
H2 blockers 611 −8 48 (107) 0.66 10 (15) 0.52
Proton pump inhibitors 194 10 −113 (114) 0.33 −2 (17) 0.91
MSICU
H2 blockers 329 1 −82 (53) 0.14 3 (8) 0.75
Proton pump inhibitors 924 −8 301 (151) 0.061 4 (21) 0.86
TNICU, trauma and neurosurgery intensive care unit; MSICU, medical surgical intensive care unit.
Table 5 Comparison of clinical outcomes in each intervention unit in the pre- and post-intervention periods.
Unit Variable Pre-intervention Post-intervention p-value
TNICU
Discharges n = 1302 n = 1358
ICU mortality 86 (7) 115 (8) 0.069
ICU length of stay in days, mean (SD) 4.7 (0.6) 4.6 (0.6) 0.38 a
Readmission to unit within 48 hours 17 (2) 19 (2) 0.81
MSICU
Discharges n = 1247 n = 1307
ICU mortality 140 (11) 147 (11) 0.99
ICU length of stay in days, mean (SD) 5.5 (0.8) 5.4 (1.0) 0.76 a
Readmission to unit within 48 hours 28 (3) 33 (3) 0.62
Data are number (%) unless otherwise indicated. All p-values calculated using Chi-square unless otherwise noted. SD = standard deviation; TNICU, trauma and
neurosurgery intensive care unit; MSICU, medical surgical intensive care unit.
aWilcoxon rank sum test
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not appear large enough to explain the inability to re-
duce antimicrobial use in this unit. There were no dis-
cernable clinically relevant changes in the types of
organims isolated during the study period. Furthermore,
there were no outbreaks in any of the intervention or
control units throughout the study period with the ex-
ception of a vancomycin-resistant Enterococcus outbreak
in the MSICU involving ten patients in the pre-
intervention period. This represented colonization rather
than clinical infection in the majority of cases and was
Table 6 Susceptibility of E. coli and P. aeruginosa isolates to commonly used antibiotics.
Unit Organism and antibiotic Pre-intervention Post-intervention p-value
TNICU
E. coli
ampicillin 42/83 (51) 40/76 (53) 0.80
cefazolin 70/83 (84) 61/76 (80) 0.50
cefotaxime 72/83 (87) 64/76 (84) 0.65
ciprofloxacin 68/83 (82) 60/76 (79) 0.64
TMP-SMX 66/83 (80) 61/76 (80) 0.91
piperacillin-tazobactam 70/83 (84) 63/76 (83) 0.81
imipenem 85/85 (100) 76/77 (99) 0.48a
gentamicin 77/83 (93) 70/76 (92) 0.87
tobramycin 76/83 (92) 70/76 (92) 0.90
P. aeruginosa
ceftazidime 27/30 (90) 22/23 (96) 0.62a
ciprofloxacin 27/30 (90) 18/23 (78) 0.27a
piperacillin-tazobactam 27/30 (90) 22/23 (96) 0.62a
imipenem 30/30 (100) 20/23 (87) 0.076a
gentamicin 28/30 (93) 23/23 (100) 0.50a
tobramycin 30/30 (100) 23/23 (100) -
MSICU
E. coli
ampicillin 37/95 (39) 30/81 (37) 0.79
cefazolin 65/95 (68) 59/81 (73) 0.52
cefotaxime 73/95 (77) 64/81 (79) 0.73
ciprofloxacin 46/95 (48) 49/81 (60) 0.11
TMP-SMX 58/95 (61) 43/81 (53) 0.29
piperacillin-tazobactam 64/95 (67) 59/80 (74) 0.36
imipenem 93/95 (98) 81/82 (99) 1.00a
gentamicin 76/95 (80) 73/81 (90) 0.063
tobramycin 72/95 (76) 72/81 (89) 0.025
P. aeruginosa
ceftazidime 50/64 (78) 42/58 (72) 0.46
ciprofloxacin 58/64 (91) 41/58 (71) 0.0049
piperacillin-tazobactam 50/64 (78) 40/58 (69) 0.25
imipenem 51/64 (80) 41/58 (71) 0.25
gentamicin 58/64 (91) 48/58 (83) 0.20
tobramycin 62/64 (97) 56/58 (97) 1.00a
Data are number of isolates susceptible/total number of isolates tested (%). All p-values calculated using Chi-square unless otherwise noted. A Bonferroni
corrected significance threshold of 0.0033 was used. TMP-SMX, trimethoprim-sulfamethoxazole.
aFisher’s Exact test
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therefore unlikely to have significantly influenced anti-
microbial prescribing. Thus there were likely other fac-
tors involved in the differential outcomes between the
TNICU and MSICU.
As expected, there were no significant changes in clin-
ical outcomes including in-ICU mortality, ICU length of
stay and 48 hour ICU readmission rates. There was a
trend toward increased mortality in the TNICU,
however, the post-intervention mortality rate was in
line with TNICU annual mortality rates over the
preceding 5 years, which have ranged from 6.6-8.4%.
Nevertheless, with any intervention aimed at redu-
cing inappropriate use, it is critical to ensure that
there are no direct harms resulting from the inter-
vention and we continue to monitor this metric. The
lack of change in resistance patterns was not unex-
pected. Although stewardship interventions have
been associated with protection against the emer-
gence of resistance, a longer follow up period may
be required to appreciate changes in ICU ecology
[14]. This was demonstrated by Geissler et al. who
found that a reduction in nosocomial infections due
to antimicrobial resistant organisms was only ob-
served 3 years after implementation of an interven-
tion [27].
The trend toward reduction in rates of Clostridium
difficile infection seen in both intervention ICUs seemed
promising, however, rates in the control ICUs were also
reduced. Therefore, the reduction was likely unrelated to
the intervention. This finding highlights the importance
of including controls in quasi-experimental antimicrobial
stewardship research, as the incidence of a variety of
outcomes, including C. difficile, may be due to regres-
sion to the mean, changes in local epidemiology, or non-
stewardship interventions (e.g. improved hand hygiene
or environmental cleaning). In our hospital, infection
prevention and control interventions remained constant
throughout the study period.
Our study had several limitations. First, our interven-
tion occurred on weekdays only and thus may underesti-
mate the potential benefit of audit and feedback. In
addition, the ideal primary outcome would be appropri-
ateness of antimicrobial therapy, rather than antimicro-
bial use. However, evaluating appropriateness is
subjective and labor intensive, and given that the litera-
ture has consistently shown that antimicrobials are
overused, a reduction in antimicrobial use, under the
supervision of an infectious diseases physician and infec-
tious diseases trained pharmacist, was a rational goal
[28]. Furthermore, the use of DDDs to quantify anti-
microbial use can be problematic, since critically ill pa-
tients may routinely receive higher daily doses for
certain agents than those defined by the WHO [29]. It is
possible that by converting to narrower agents, the
defined daily doses will actually increase. Finally, as with
many studies in the field of antimicrobial stewardship,
temporal confounding is a concern. However, our con-
trolled, interrupted time series design is more robust
than the before and after analyses or uncontrolled inter-
rupted time series designs used in most stewardship
studies [20].
Conclusions
Our results demonstrate the potential for audit and feed-
back to significantly reduce antimicrobial use in some,
but not all, ICU settings. We also demonstrate the im-
portance of a controlled study design in assessing the
impact of stewardship on a variety of clinical outcomes,
including C. difficile incidence. Additional research is re-
quired to understand the predictors of success for spe-
cific stewardship interventions.
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